Actym Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
626 Bancroft Way Ste A, Berkeley, Califo...Phone Number
(415) 637-6691Website
www.actymthera.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Actym Therapeutics
Actym Therapeutics specializes in bacterial immunotherapy and cancer treatment solutions, utilizing a biologically engineered bacteria drug delivery platform. The company is advancing its STACT (Anti-Cancer Therapy) platform, which is currently in a phase 1 clinical trial for treating advanced solid tumors. Their mission is to harness bacterial intelligence to create therapeutics that significantly impact cancer and fibrotic disease treatment. Actym aims to deliver multiple therapeutic payloads locally at disease sites, minimizing systemic toxicity.Explore more
Actym Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Actym Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Actym Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Actym Therapeutics
Click to see if Actym Therapeutics had a recent Job posting/layoffs
Actym Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Actym Therapeutics is spiking on competitors!
Check if Actym Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Actym Therapeutics has new funding data
Product Launch: Get notified when Actym Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Actym Therapeutics
Compare insights from companies similar to Actym Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Actym Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Actym Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Actym Therapeutics.
Actym Therapeutics financials insights
Gather financial insights about Actym Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$197K
2023
Series A
$59.9M
Actym Therapeutics Tech Stack
A closer look at the technologies used by Actym Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Open Position
New Hire
Executive Move
Executive Moves, New Hire
Open Position
Actym Therapeutics News & Media
Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies
Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym's pipeline Shouryadeep "Deep" Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym's clinical activities BERKELEY, Calif., June 25, 2024 /PRNewswire/ --...Actym Therapeutics Appoints Thomas Smart as CEO
BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of...Actym to Present Preclinical Data on Clinical Candidate ACTM-838 at 38th SITC Annual Meeting
BERKELEY, Calif., Nov. 3, 2023 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today that it will present preclinical data of its lead asset, ACTM-838, in a poster presentation at the 2023 38th Society for Immunotherapy of Cancer (SITC)...Actym Closes $59.5 Million Series A with New $25.5 Million Extension
Actym Therapeutics adds $25.5 million to close its Series A with $59.5 million total New investor GKCC LLC joins syndicate Capital will propel lead program ACTM-838 into first-in-human oncology trial and further advance proprietary STACT platform BERKELEY, Calif., Oct. 18, 2023...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Actym Therapeutics
Sign Up For FreeTo access detailed company insights
Actym Therapeutics specializes in bacterial immunotherapy and cancer treatment solutions, utilizing a biologically engineered bacteria drug delivery platform. The company is advancing its STACT (Anti-Cancer Therapy) platform, which is currently in a phase 1 clinical trial for treating advanced solid tumors. Their mission is to harness bacterial int... Read More
